Cover Image
市場調查報告書

亨丁頓蛋白(Huntingtin):開發中產品分析

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358692
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
亨丁頓蛋白(Huntingtin):開發中產品分析 Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 56 Pages
簡介

本報告提供全球各國治療亨丁頓蛋白(Huntingtin) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 亨丁頓蛋白(Huntingtin)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • 亨丁頓蛋白(Huntingtin)的治療藥開發企業
    • AFFiRiS AG
    • Ionis Pharmaceuticals, Inc.
    • Neurimmune Holding AG
    • nLife Therapeutics, S.L.
    • reMYND NV
    • Sangamo BioSciences, Inc.
    • UniQure N.V.
    • Voyager Therapeutics, Inc.
    • Vybion, Inc.
    • WAVE Life Sciences Ltd.
  • 藥物簡介
    • AMT-130
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • 亨丁頓舞蹈症蛋白質抑制用的反義寡核甘酸1
    • 亨丁頓舞蹈症蛋白質抑制用的反義寡核甘酸2
    • 亨丁頓舞蹈症HTT抑制用的反義寡核甘酸
    • 亨丁頓舞蹈症蛋白質抑制用的反義寡核甘酸
    • 亨丁頓舞蹈症蛋白質抑制用的基因治療
    • INT-41
    • IONIS-HTTRx
    • NI-302
    • 亨丁頓舞蹈症蛋白質抑制用的小分子
    • 亨丁頓舞蹈症蛋白質抑制用疫苗
    • VYHTT-01
  • 開發暫停的計劃
  • 值得注意的最新趨勢·新聞稿 (全7件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0527TDB

Summary

Global Markets Direct's, 'Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016', provides in depth analysis on Huntingtin (Huntington Disease Protein or HTT) targeted pipeline therapeutics.

The report provides comprehensive information on the Huntingtin (Huntington Disease Protein or HTT), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein or HTT)
  • The report reviews Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein or HTT)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein or HTT) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Huntingtin (Huntington Disease Protein or HTT) Overview
  • Therapeutics Development
    • Huntingtin (Huntington Disease Protein or HTT) - Products under Development by Stage of Development
    • Huntingtin (Huntington Disease Protein or HTT) - Products under Development by Therapy Area
    • Huntingtin (Huntington Disease Protein or HTT) - Products under Development by Indication
  • Huntingtin (Huntington Disease Protein or HTT) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Huntingtin (Huntington Disease Protein or HTT) - Products under Development by Companies
  • Huntingtin (Huntington Disease Protein or HTT) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Huntingtin (Huntington Disease Protein or HTT) - Companies Involved in Therapeutics Development
    • AFFiRiS AG
    • Ionis Pharmaceuticals, Inc.
    • Neurimmune Holding AG
    • nLife Therapeutics, S.L.
    • reMYND NV
    • Shire Plc
    • UniQure N.V.
    • Voyager Therapeutics, Inc.
    • Vybion, Inc.
    • WAVE Life Sciences Ltd.
  • Huntingtin (Huntington Disease Protein or HTT) - Drug Profiles
    • AMT-130 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide 2 to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit HTT for Huntington's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-41 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-HTTRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Huntingtin for Huntington's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VYHTT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WVE-120101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Huntingtin (Huntington Disease Protein or HTT) - Dormant Projects
  • Huntingtin (Huntington Disease Protein or HTT) - Featured News & Press Releases
    • Aug 24, 2016: Novel Gene Therapy Drug for Huntington Disease
    • Jun 21, 2016: WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington's Disease
    • Mar 22, 2016: uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington's Disease
    • Jan 05, 2016: Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington Disease
    • Jul 21, 2015: Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
    • Nov 19, 2014: Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
    • Nov 12, 2013: Sangamo BioSciences Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP Therapeutic For Huntington's Disease
    • Sep 03, 2013: Vybion's Huntington Drug Neutralizes Critical Disease Driver
    • Oct 17, 2012: Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic For Huntington's Disease At 2012 Annual Meeting Of Society For Neuroscience
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by AFFiRiS AG, H2 2016
  • Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Pipeline by Neurimmune Holding AG, H2 2016
  • Pipeline by nLife Therapeutics, S.L., H2 2016
  • Pipeline by reMYND NV, H2 2016
  • Pipeline by Shire Plc, H2 2016
  • Pipeline by UniQure N.V., H2 2016
  • Pipeline by Voyager Therapeutics, Inc., H2 2016
  • Pipeline by Vybion, Inc., H2 2016
  • Pipeline by WAVE Life Sciences Ltd., H2 2016
  • Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top